Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAWN: Dorzagliatin Add-on to Metformin in Type 2 Diabetes
NCT03141073Phase 3Completed
- Sponsor
- Hua Medicine
- Start
- Oct 2017
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing HMS5552 + Metformin with Placebo + Metformin (2 arms). Primary endpoint: Change from baseline in HbA1c at 24 weeks. Started Oct 2017; status: completed.
02
Drugs
dorzagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03141073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03141073.